$AMDA Recent Company Highlights: Cash and cash
Post# of 13123
Cash and cash equivalents totaled $11.3 million, and net cash used in operating activities during the quarter decreased by $1.3 million, or 43%, from the prior year period
Reduced debt principal balance by $3.5 million, or 14%, and eliminated conversion feature of the convertible note
Two-year performance data from the CASCADE clinical trial submitted to the U.S. Food and Drug Administration (FDA), with an anticipated final response in the first quarter of 2016
Received Brazilian clearance and shipped initial order of first generation silicon nitride interbody devices and instrumentation
Appointed world-renowned materials scientist Giuseppe Pezzotti, PhD to the Scientific Advisory Board
Launched Valeo II™ lateral lumber interbody fusion device system and innovative articulating inserter for minimally invasive TLIF procedures
Finalized definitive agreements to raise up to $15 million in equity financing, which will strengthen the Company’s balance sheet, reduce debt and be used for working capital
http://www.otcmarkets.com/stock/AMDA/news
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)